Document:

EX-10.2

 Exhibit 10.2 

AMENDMENT NO. 2 
 TO 
 EMPLOYMENT AGREEMENT 

This AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (this “Amendment”) is made as of October 18, 2012, by Burlington Coat
Factory Warehouse Corporation, a Delaware corporation (the “Company”) and Joyce Manning Magrini (“Executive”). 
 W I T N E S S E T H. 
 WHEREAS, the parties hereto entered into that
certain Employment Agreement, dated as of October 13, 2009 (the “Employment Agreement”) (capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Employment Agreement); and

 WHEREAS, the parties hereto desire to amend the Employment Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Section 4(c) of the Employment
Agreement is hereby amended by deleting the entire section thereof and replacing it with the following: 
 “(c) Executive
agrees that: (i) Executive shall be entitled to the payments and services provided for in Sections 4(b)(i)(3), 4(b)(i)(4), and 4(b)(i)(5), if any, if and only if Executive has executed and delivered the Release (and no
longer subject to revocation, if applicable) attached as Exhibit A within sixty days following the date of termination and Executive has not breached as of the date of termination of the Employment Period the provisions of Sections 5,
6 and 7 hereof and does not breach such sections or such covenants at any time during the period for which such payments or services are to be made; and (ii) the Company’s obligation to make such payments and services will
terminate upon the occurrence of any such breach during such period.” 
 2. Section 4(d) of the Employment Agreement
is hereby amended by deleting the entire section thereof and replacing it with the following: 
 “(d) Except as stated
above, any payments pursuant to Section 4(b) shall be paid by the Company in regular installments in accordance with the Company’s general payroll practices, and following such payments the Company shall have no further obligation
to Executive pursuant to this Section 4 except as provided by law; provided that to the extent that the payment of any amount constitutes “nonqualified deferred compensation” for purposes of Section 409A of the Code
(as defined in subsection (g) hereof), any such payment scheduled to occur during the first sixty (60) days following the termination of employment shall not be paid 

 
until the first regularly scheduled pay period following the sixtieth (60th) day following such termination and shall include payment of any amount that was otherwise scheduled to be paid
prior thereto. All amounts payable to Executive as compensation hereunder shall be subject to all customary withholding, payroll and other taxes. The Company shall be entitled to deduct or withhold from any amounts payable to Executive any federal,
state, local or foreign withholding taxes, excise tax, or employment taxes imposed with respect to Executive’s compensation or other payments or Executive’s ownership interest in the Company (including, without limitation, wages, bonuses,
dividends, the receipt or exercise of equity options and/or the receipt or vesting of restricted equity).” 
 3.
Section 21 is hereby added at the end thereof: 
 “21. Section 409A. The intent of the parties is that
payments and benefits under this Agreement comply with Section 409A of the Code and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. In no event whatsoever shall the Company be
liable for any additional tax, interest or penalty that may be imposed on the Executive by Section 409A of the Code or damages for failing to comply with Section 409A of the Code. To the extent that reimbursements or other in-kind benefits
under this Agreement constitute “nonqualified deferred compensation” for purposes of Code Section 409A, (A) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following
the taxable year in which such expenses were incurred by the Executive, (B) any right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (C) no such reimbursement, expenses
eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year. For purposes of Code Section 409A, the
Executive’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with
reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company. Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this
Agreement that constitutes “nonqualified deferred compensation” for purposes of Code Section 409A be subject to offset by any other amount unless otherwise permitted by Code Section 409A.” 

4. Except as specifically set forth herein, the Agreement and all of its terms and conditions remain in full force and effect, and the
Agreement is hereby ratified and confirmed in all respects, except that on or after the date of this Amendment all references in the Agreement to “this Agreement,” “hereto,” “hereof,” “hereunder,” or words of
like import shall mean the Agreement as amended by this Amendment. 

  
 2 

 5. This Amendment may be executed in any number of counterparts, each of which shall be
deemed an original and such counterpart together shall constitute one and the same instrument. 
 6. This Amendment, including
the validity, interpretation, construction and performance of this Amendment, shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such State, without regard to
such State’s conflicts of law principles. 
 7. This Amendment shall be binding upon and inure to the benefit of and be
enforceable by the respective successors and assigns of the parties hereto. The Agreement, as amended by this Amendment, embodies the entire agreement and understanding between the parties hereto and supersedes all prior agreements and
understandings relating to the subject matter hereof. 
 [remainder of page intentionally left blank; signature page follows]

  
 3 

 SIGNATURE PAGE TO AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above. 

 

			
	BURLINGTON COAT FACTORY WAREHOUSE CORPORATION
		
	By:	 	 /s/ Paul Tang

	Name:	 	Paul Tang
	Title:	 	Executive Vice President
	
	 /s/ Joyce Manning Magrini

	Joyce Manning Magrini

  
 4Second Supplemental Indenture, dated as of December 11, 2012

 Exhibit 4.1 
 EXECUTION VERSION 
 SUPPLEMENTAL INDENTURE 

 
  
 MEDICIS PHARMACEUTICAL CORPORATION 
 1.5% Contingent Convertible Senior
Notes Due 2033 
  
  

SECOND SUPPLEMENTAL INDENTURE 
 DATED AS OF DECEMBER 11, 2012 
  

 
 Deutsche Bank
Trust Company Americas as Trustee 
  
  

 SECOND SUPPLEMENTAL INDENTURE 

SECOND SUPPLEMENTAL INDENTURE (“Supplemental Indenture”) dated as of December 11, 2012, between Medicis
Pharmaceutical Corporation, a Delaware corporation (the “Company”), and Deutsche Bank Trust Company Americas, a New York banking corporation (the “Trustee”). 

RECITALS OF THE COMPANY 
 WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of August 19, 2003 (the “Base Indenture”), pursuant to which the Company issued its 1.5% Contingent
Convertible Senior Notes Due 2033 (the “Notes”), and to an appurtenant supplemental indenture, dated as of February 1, 2005 (the “First Supplemental Indenture,” and the Base Indenture, as amended, modified or
supplemented by the First Supplemental Indenture being referred to as the “Indenture”); 
 WHEREAS, on
September 2, 2012, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Valeant Pharmaceuticals International, a Delaware corporation (“Valeant”), Valeant Pharmaceuticals
International, Inc., a Canadian corporation, and Merlin Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Valeant (“Merger Sub”); 
 WHEREAS, pursuant to the Merger Agreement and subject to the terms and conditions therein, Merger Sub will merge with and into the Company (the “Merger”) and the Company will continue as
a wholly owned subsidiary of Valeant; 
 WHEREAS, pursuant to the Merger Agreement and subject to the terms and conditions
therein, at the effective time of the Merger, each share of Class A Common Stock of the Company will be converted into the right to receive $44.00 in cash, without interest and less any applicable withholding taxes; 

WHEREAS, in connection with the foregoing, Sections 9.01(c) and 10.12 of the Indenture provide that the Company shall execute a
supplemental indenture providing that each Note shall, without the consent of any Holder of Notes, become convertible into the kind and amount of cash, securities or other property or assets receivable upon the Merger by a holder of a number of
shares of Class A Common Stock deliverable upon conversion of such Note; and 
 WHEREAS, all conditions for the execution
and delivery of this Supplemental Indenture have been complied with or have been done or performed. 

  
 -2-

 NOW, THEREFORE, THIS INDENTURE WITNESSETH: 

For and in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, it is mutually covenanted and agreed, for the equal proportionate benefit of all Holders of the Notes, as follows: 

ARTICLE 1 

Definitions 
 Section 1.01 General. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Indenture. 

ARTICLE 2 

Agreements of Parties 
 Section 2.01 Closing Price. The definition of the Closing Price with respect to Class A Common Stock in Section 10.06 of the Indenture is hereby deleted and replaced in its entirety
with the following: 
 “Closing Price” means, with respect to Class A Common Stock, $44.00. 

Section 2.02 Conversion of Notes. In accordance with Section 10.12 of the Indenture and the Officers’ Certificate,
dated December 11, 2012, from and after the date of this Supplemental Indenture, the right to convert each $1,000 principal amount of Notes will be changed to a right to convert such Notes by reference to the kind and amount of cash, securities
or other property or assets that a holder of a number of shares of Class A Common Stock equal to (i) $1,000 divided by (ii) the Conversion Price of $38.76, or 25.7998 shares, immediately prior to the Merger would have owned or been
entitled to receive (the “Reference Property”), which will be cash equal to $1,135.19 per $1,000 principal amount of Notes. Accordingly, any reference to a share of Class A Common Stock in the Indenture shall be deemed a
reference to a right to receive an amount in cash equal to $44.00, and the provisions of the Indenture, as modified herein, shall continue to apply, mutatis mutandis, to the Holders’ right to convert the Notes into the Reference
Property. 
 ARTICLE 3 
 Miscellaneous Provisions 
 Section 3.01 Effectiveness;
Construction. This Supplemental Indenture shall become effective upon its execution and delivery by the Company and the Trustee and as of the date hereof. Upon such effectiveness, the Indenture shall be supplemented in accordance herewith. This
Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered under the Indenture shall be bound thereby. The Indenture and this Supplemental Indenture shall
henceforth be read and construed together. 

  
 -3-

 Section 3.02 Indenture Remains in Full Force and Effect. Except as supplemented
hereby, all provisions in the Indenture shall remain in full force and effect. 
 Section 3.03 Trustee Matters. The
Trustee accepts the Indenture, as supplemented hereby, and agrees to perform the same upon the terms and conditions set forth therein, as supplemented hereby. The Trustee shall be entitled to the benefit of every provision of the Indenture relating
to the conduct or affecting the liability or affording protection to the Trustee, whether or not elsewhere herein so provided. The recitals contained in this Supplemental Indenture shall be taken as the statements of the Company and the Trustee
assumes no responsibility for their correctness. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture. 
 Section 3.04 No Third-Party Beneficiaries. Nothing in this Supplemental Indenture, express or implied, shall give to any Person, other than the parties to the Indenture, as supplemented
hereby, and their successors, and to the Holders of the Notes, any benefit of any legal or equitable right, remedy or claim under the Indenture, as supplemented hereby. 
 Section 3.05 Severability. In case any provision of this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not be impaired thereby. 
 Section 3.06 Headings. The Article and Section headings of this
Supplemental Indenture have been inserted for convenience of reference only and are not to be considered a part of this Supplemental Indenture and shall in no way modify or restrict any of the terms or provisions hereof. 

Section 3.07 Successors. All agreements of the Company and the Trustee in this Supplemental Indenture shall bind their
respective successors. 
 Section 3.08 Governing Law. This Supplemental Indenture shall be construed in accordance
with the laws of the State of New York, without regard to conflicts of laws principles thereof. 
 Section 3.09
Counterpart Signatures. This Supplemental Indenture may be signed by the parties hereto in multiple counterparts. Each signed counterpart shall be deemed an original, but all of them together shall represent the same agreement. 

  
 -4-

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

					
	MEDICIS PHARMACEUTICAL CORPORATION
		
	By:	 	 /s/ Mark A. Prygocki

		 	Name:	 	Mark A. Prygocki
		 	Title:	 	President

 
			
	DEUTSCHE BANK TRUST COMPANY
AMERICAS
	
	By: Deutsche Bank National Trust Company
		
	By:	 	 /s/ Jeffrey Schoenfeld

		 	Name: Jeffrey Schoenfeld
		 	Title:   Associate
		
	By:	 	 /s/ Kelvin Vargas

		 	Name: Kelvin Vargas
		 	Title:   Associate

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]